Halozyme Therapeutics Valuation
| HALO Stock | USD 48.47 0.68 1.42% |
At this time, the firm appears to be overvalued. Halozyme Therapeutics retains a regular Real Value of $42.51 per share. The prevalent price of the firm is $48.47. Our model calculates the value of Halozyme Therapeutics from evaluating the firm fundamentals such as Return On Asset of 0.15, return on equity of 1.12, and Current Valuation of 7 B as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Halozyme Therapeutics' valuation include:
Price Book 13.6219 | Enterprise Value 7 B | Enterprise Value Ebitda 12.0673 | Price Sales 6.5094 | Forward PE 11.1111 |
Overvalued
Today
Please note that Halozyme Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Halozyme Therapeutics is based on 3 months time horizon. Increasing Halozyme Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Halozyme Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Halozyme Stock. However, Halozyme Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 48.47 | Real 42.51 | Target 51.9 | Hype 48.47 | Naive 44.26 |
The intrinsic value of Halozyme Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Halozyme Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Halozyme Therapeutics helps investors to forecast how Halozyme stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Halozyme Therapeutics more accurately as focusing exclusively on Halozyme Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Halozyme Therapeutics' intrinsic value based on its ongoing forecasts of Halozyme Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Halozyme Therapeutics' closest peers.
Halozyme Therapeutics Cash |
|
Halozyme Valuation Trend
Knowing Halozyme Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Halozyme Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Halozyme Revenue by Product
Halozyme Therapeutics Total Value Analysis
Halozyme Therapeutics is currently expected to have valuation of 7 B with market capitalization of 6.17 B, debt of 1.5 B, and cash on hands of 209.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Halozyme Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
7 B | 6.17 B | 1.5 B | 209.36 M |
Halozyme Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company had not issued any dividends in recent years. Halozyme Therapeutics had 171:40 split on the 10th of December 2003. Based on the key indicators related to Halozyme Therapeutics' liquidity, profitability, solvency, and operating efficiency, Halozyme Therapeutics is performing exceptionally good at this time. It has a great odds to report excellent financial results in December.Halozyme Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Halozyme Therapeutics has an asset utilization ratio of 47.84 percent. This suggests that the Company is making $0.48 for each dollar of assets. An increasing asset utilization means that Halozyme Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Halozyme Therapeutics Ownership Allocation
The majority of Halozyme Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Halozyme Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Halozyme Therapeutics. Please pay attention to any change in the institutional holdings of Halozyme Therapeutics as this could imply that something significant has changed or is about to change at the company. On October 4, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Halozyme Therapeutics's common stock.Halozyme Therapeutics Profitability Analysis
The company reported the previous year's revenue of 829.25 M. Net Income was 281.59 M with profit before overhead, payroll, taxes, and interest of 454.2 M.About Halozyme Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Halozyme Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Halozyme Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Halozyme Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Halozyme Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Halozyme Therapeutics. We calculate exposure to Halozyme Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Halozyme Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 636.9 M | 668.7 M | |
| Pretax Profit Margin | 0.42 | 0.44 | |
| Operating Profit Margin | 0.41 | 0.43 | |
| Net Profit Margin | 0.34 | 0.36 | |
| Gross Profit Margin | 0.77 | 0.61 |
Halozyme Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 134.2 M | |
| Quarterly Earnings Growth Y O Y | 0.721 | |
| Forward Price Earnings | 11.1111 |
Halozyme Therapeutics Current Valuation Indicators
Halozyme Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Halozyme Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Halozyme Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Halozyme Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Halozyme Therapeutics' worth.When determining whether Halozyme Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Halozyme Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Halozyme Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Halozyme Therapeutics Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.